Roivant SciencesROIV

We expect revenue to grow from $0.0B in FY2026 to $4.7B in FY2031 (~249% CAGR), with EPS growing from $-1.12 to $2.40. Revenue scales as the company launches its pipeline of immunology and inflammation drugs into large commercial markets. Operating margins improve as the company leverages its centralized platform to manage multiple drug launches without doubling corporate overhead. EPS grows faster than revenue because the business shifts from an expensive research phase to a high-margin commercial phase. Operating margin expected to reach ~35% by FY2031.

IMVT-1402 becomes the best-in-class treatment for autoimmune diseases. If clinical data continues to show superior safety and efficacy, this drug could capture billions in the multi-indication immunology market.

Successful commercial launch of brepocitinib in September 2026. A strong launch would prove Roivant can sell drugs as effectively as it develops them, re-rating the company's valuation.

Collection of $2.25 billion Moderna settlement cash. This massive cash infusion provides enough capital to reach profitability without ever needing to issue new shares.

Clinical trial failure for IMVT-1402 in late-stage studies. If the drug fails to meet its primary goals in upcoming Phase 3 trials, the company's primary growth engine would disappear.

Regulatory rejection or delays for brepocitinib launch. Any delay from the FDA beyond the September 2026 target would burn cash and damage management's credibility.

Intense competition from argenx and large pharma giants. If competitors lower prices or launch better drugs first, Roivant's market share and margins could be permanently squeezed.

Detailed deep dive on earnings update reports will be available soon for Pro members.

We use a 5-year Discounted Cash Flow (DCF) with a terminal multiple to value the business. It fits Roivant because the company is currently in a heavy investment phase with minimal current revenue, making standard trailing multiples or forward P/E based on near-term losses irrelevant for long-term valuation.

Applying a 27x terminal multiple to the FY2031 EPS projection of $2.40 yields a future value that discounts back to a $40 present value. The 27x multiple sits at the mid-point of specialized biotech peers—between Regeneron at 22x and Vertex at 28x—reflecting Roivant’s diversified pipeline potential balanced by its lack of a long-term commercial track record. We used the FY2031 EPS basis of $2.40 from the deterministic engine to ensure this valuation aligns with the projected timeline of drug approvals and market entry.

Cross-checked with an EV/Revenue approach (FY2031 revenue $4.7B × 6x peer multiple), we arrive at a fair value of $39 — within 3% of our $40 DCF answer, confirming the result. A 6x revenue multiple is the standard for high-growth biologics companies with protected intellectual property. This close alignment between the cash-flow-based DCF and the revenue-based cross-check suggests that the $40 target is a robust estimate of the company's fundamental value upon reaching commercial maturity.

We're assuming Roivant scales from current negligible revenue to $4.7B by FY2031. This trajectory is supported by the maturation of multiple immunology and dermatology assets currently in late-stage trials, which are projected to reach peak commercialization toward the end of the decade.

We're assuming a 10% discount rate (WACC) to account for the inherent risks of biotech development. While Roivant maintains a strong net-cash balance sheet with $1.42B in liquidity, the double-digit discount rate is necessary to reflect the binary clinical and regulatory risks associated with pre-revenue drug candidates.

We're assuming the "Vant" model—launching independent subsidiaries for specific drugs—continues to generate operational efficiency. This decentralized approach has historically allowed Roivant to move faster than traditional big pharma, justifying a premium growth rate as more assets transition from the laboratory to the pharmacy shelf.

The biggest risk is the high probability of clinical trial failure for mid-to-late stage drugs within the "Vant" pipeline. Such a failure would invalidate the aggressive 2031 revenue projections, potentially cutting the fair value by 50% to roughly $20 per share. Investors should closely monitor Phase 3 readout dates for the immunology portfolio to detect early signs of impairment.